Avalo Therapeutics (AVTX)
(Real Time Quote from BATS)
$9.80 USD
+0.13 (1.34%)
Updated Sep 24, 2024 12:20 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AVTX 9.80 +0.13(1.34%)
Will AVTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVTX
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?
AVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for AVTX
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
Avalo Announces Participation in September Investor Conferences
Avalo Therapeutics trading resumes
Avalo Therapeutics trading halted, volatility trading pause
Oppenheimer Sticks to Their Buy Rating for Avalo Therapeutics (AVTX)